Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Chronic inflammatory demyelinating polyneuropathy


Other Names for this Disease

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might chronic inflammatory demyelinating polyneuropathy (CIDP) be treated?

Treatment for CIDP includes:[1][2]  

 

  • Corticosteroids such as prednisone to help reduce inflammation and relieve symptoms
  • Medications that suppress the immune system (azathioprine, methotrexate, mycophenolate, cyclosporine, and cyclophosphamide)
  • Removal of antibodies from the blood through plasmapheresis or plasma exchange
  • Intravenous immunoglobulin (IVIg) therapy, which adds large numbers of antibodies to the blood plasma to reduce the effect of the antibodies 
  • Physiotherapy to improve muscle strength, function and mobility, and minimize the shrinkage of muscles and tendons and distortions of the joints

 

Detailed information about management options can be accessed through the Treatment and Medication sections of Medscape Reference.
Last updated: 8/1/2012

References
  1. NINDS Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page. National Institute of Neurological Disorders and Stroke (NINDS). 2011; http://www.ninds.nih.gov/disorders/cidp/cidp.htm. Accessed 8/1/2012.
  2. Chronic inflammatory polyneuropathy. MedlinePlus. 2010; http://www.nlm.nih.gov/medlineplus/ency/article/000777.htm. Accessed 8/1/2012.


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Chronic inflammatory demyelinating polyneuropathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Immune Globulin (Human)
Trade Name
(Manufacturer Name)
Gamunex®
(Talecris)
Indication
The FDA has approved this product to be used in this manner.
Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.